In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program. 

Related News Articles

Headline
The Coalition to Protect America’s Health Care, of which the AHA is a founding member, is continuing to run TV and digital ads urging Congress not to cut…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 29 held a hearing on legislative proposals to expand access to treatment for patients with rare…
Headline
The House Feb. 29 voted 320-99 to pass a continuing resolution that would extend funding through March 8 for four appropriations bills set to expire March 1…
Headline
Bipartisan, bicameral leaders of the House and Senate and their Appropriations Committees Feb. 28 announced an agreement to extend funding through March 8 for…
Perspective
Two presidents that America honors with a federal holiday on Monday shared a number of memorable traits. George Washington and Abraham Lincoln were blessed…
Headline
AHA Feb. 15 reiterated its support for the Future Advancement of Academic Nursing Act, recently reintroduced by Sen. Jeff Merkley, D-Ore., and Rep. Lauren…